New stock news | Exegenesis Bio Inc. files for listing on the Hong Kong Stock Exchange.
On January 14, Exegenesis Bio Inc. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Haitong International as its sole sponsor.
On January 14th, Exegenesis Bio Inc. submitted an application to the Hong Kong Stock Exchange for listing, with China International Capital Corporation acting as its exclusive sponsor. According to the prospectus, Exegenesis Bio Inc. has developed a diversified and scalable product pipeline using its independently developed AAVarta and SODA technology platforms, including the core candidate product EXG001-307 (SMA Type 1) and two key candidate products, EXG102-031 and EXG202.
Related Articles
CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.
FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.
MNSO (09896) spent $235,600 to repurchase 55,600 shares on March 10th.
CATHAY PAC AIR (00293) will distribute its second interim dividend of 0.64 Hong Kong dollars per share on May 7th.
FE HORIZON (03360) released its 2025 annual performance, with a net profit attributable to shareholders of 3.889 billion yuan, a year-on-year increase of 0.67%.
MNSO (09896) spent $235,600 to repurchase 55,600 shares on March 10th.
RECOMMEND
Local Policies Experiment With “Lobster” AI Agents Accelerate Into The Agent Era But Security Risks Remain
10/03/2026
Hong Kong And Macau Join Billion‑Level Guidance Fund Initiative Hong Kong Sets Return‑Investment KPI Macau Targets MOP 20 Billion
10/03/2026
Southbound Capital Sells Heavily Yet Hang Seng Tech Advances How Do Fund Managers Interpret It
10/03/2026
